Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Thalidomide and Capecitabine vs Supportive Therapy in Unresectable HCC
NCT01438450Phase 3Unknown
- Sponsor
- AIIMS New Delhi
- Start
- Oct 2007
- Primary completion
- Aug 2013
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of thalidomide, capecitabine in hepatocellular carcinoma (HCC), sponsored by AIIMS New Delhi. Status: unknown.
02
Drugs
thalidomidecapecitabine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01438450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01438450.